C-1YVUpartial epigenetic reprogramming, cellular rejuvenation, OSK gene therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Could scientists actually reverse aging at the cellular level? In this video, we explore groundbreaking anti-aging research, cellular reprogramming technology, epigenetic aging, longevity science, regenerative medicine, and the first human to receive an experimental treatment designed to help aging cells behave more like younger cells. Learn how Nobel Prize-winning discoveries involving the Yamanaka Factors are influencing cutting-edge age reversal research, glaucoma treatment, vision restoration studies, and the growing field of life extension. We also examine the potential benefits, cancer risks, safety concerns, and ethical questions surrounding one of the most talked-about breakthroughs in modern biotechnology. Is this the beginning of a real anti-aging therapy, or are scientists still decades away from unlocking the secrets of healthy aging? Primary Article • Business Insider - The First-Ever Reverse-Aging Drug Was Just Injected Into a Human Supporting Sources Referenced in Repor
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 safe when given as a single dose to people with OAG or NAION * What side effects may occur, if any, after taking ER-100? Participants will: * Receive a single dose of ER-100 * Undergo safety assessments including detailed eye examination and laboratory tests * Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body * Complete questionnaires about their quality of life * Be followed for up to 5 years to monitor long-term health and vision outcomes
In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Sharon Rosenzweig-Lipson, PhD, Chief Scientific Officer (CSO) at Life Biosciences, a company advancing cellular rejuvenation gene therapies to treat age-related diseases. The company is targeting eye diseases like glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). Dr. Rosenzweig-Lipson has held leadership positions in both big pharma and small biotechnology companies over the course of her 30+ year career, which has included roles at American Cyanamid (now Pfizer), advancing programs from the early exploratory phase through to Phase IIB. Afterwards, she spent the next 12 years at AgeneBio where she served as Vice President of R&D. Dr. Rosenzweig-Lipson is globally recognized for her scientific and strategic leadership, having led global translational alliances. She received her BA in the biological basis of behavior from the Univers
How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial. Tune in today!
Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps. An excerpt from "Manufacturing Partnership With Life Biosciences Jerry McLaughlin and Forge Biologics' John Maslowski" - check out the full video at https://www.bioprocessonline.com/doc/manufacturing-partnership-with-life-biosciences-jerry-mclaughlin-and-forge-biologics-john-maslowski-0001 --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4 Spotify - https://open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA YouTube - https://www.youtube.com/playlist?list=PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb
Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski discuss their companies’ partnership, Life’s pipeline, and Columbus’ biotech hub. An excerpt from "Manufacturing Partnership With Life Biosciences Jerry McLaughlin and Forge Biologics' John Maslowski" - check out the full video at https://www.bioprocessonline.com/doc/manufacturing-partnership-with-life-biosciences-jerry-mclaughlin-and-forge-biologics-john-maslowski-0001 --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4 Spotify - https://open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA YouTube - https://www.youtube.com/playlist?list=PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb
Jerry McLaughlin explains the vetting process he used to select Forge Biologics as a CDMO partner. An excerpt from "Manufacturing Partnership With Life Biosciences Jerry McLaughlin and Forge Biologics' John Maslowski" - check out the full video at https://www.bioprocessonline.com/doc/manufacturing-partnership-with-life-biosciences-jerry-mclaughlin-and-forge-biologics-john-maslowski-0001 --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4 Spotify - https://open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA YouTube - https://www.youtube.com/playlist?list=PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb
On this week's episode of the Business of Biotech, Jerry McLaughlin, CEO and President at Life Biosciences returns for a visit, and he brought a friend in John Maslowski, newly appointed CEO at Forge Biologics. We revisit progress at Life Biosciences, followed by a deep look into the gears that make the company's contract development and manufacturing relationship with Forge Biologics go. From CDMO selection to contracting and execution, the episode is packed with actionable insight into building a foundation for collaborative success in advanced biologic therapy development. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com. Get in touch with guest and topic suggestions: [email protected] Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/ --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - https://podcasts.apple.com/us/podcast/business-of-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Today, we have a special guest, Jerry McLaughlin, CEO of Life Biosciences. With over 30 years in the biopharmaceutical industry, Jerry has been instrumental in the development and commercialization of more than a dozen FDA-approved drugs. His impressive career started at Merck, and went on to leading roles at Endo, Neos Therapeutics, AgeneBio, and NuPathe. Life Biosciences is dedicated to extending healthy human lifespan by targeting the biological causes of aging. In this episode, we'll explore Jerry's journey from big pharma to biotech startups, his path to becoming a CEO, and the innovative work at Life Biosciences. Enjoy and stay Tuned!
In this episode, Dominika Wilczok talks with Dr Sharon Rosenzweig-Lipson, the chief scientific officer at Life Biosciences, the tier 3 sponsor of ARDD 2024! https://www.lifebiosciences.com/ 🔴Dr. Rosenzweig-Lipson is the Chief Scientific Officer for Life Biosciences, Inc. She has held leadership positions in both big pharma and small biotechnology companies over the course of her 30+year career. She has a proven track record of advancing programs from the early exploratory phase through to Phase 2B. Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer where she led a team to a successful Phase 2 proof of concept study. As VP of R&D for AgeneBio, Dr. Rosenzweig-Lipson led the clinical development of its lead asset through Phase 2B clinical trials as well as the company’s preclinical discovery program. Dr. Rosenzweig-Lipson is globally recognized for her top scientific and strategic leadership, having led global translational alliances and has a
In this episode, Ayesha spoke with Jerry McLaughlin, chief executive officer and board member of Life Biosciences, a company advancing innovative cellular rejuvenation platforms to reverse diseases of aging. Life Biosciences is developing a gene therapy for primary open-angle glaucoma (POAG) and non-arteritic anterior ischemic optic neuropathy (NAION), two types of optic neuropathies with significant unmet needs. The company is developing innovative therapies for these indications that are based on innovative partial epigenetic reprogramming and chaperone-mediated autophagy technologies. Jerry McLaughlin has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Jerry began his career at Merck and was extensively involved in multiple blockbuster product launches. Most recently, Jerry was President and CEO for Neos The
Join us as we explore the inspiring journey of Dr. Sharon Rosenzweig Lipson, a trailblazer in behavioral neuroscience and pharmaceutical leadership. With a BA from the University of Pennsylvania and a PhD from Harvard, Dr. Rosenzweig Lipson has over three decades of experience in drug development, focusing on psychiatric and neurologic conditions. Her roles at major pharmaceutical companies like Wyeth and Pfizer, and her leadership as head of R&D at AgeneBio, highlight her expertise and impact in the field. Currently, as Chief Scientific Officer at Life Biosciences, she drives innovative research and clinical development targeting the biology of aging. Listen now to hear a story about her first grade academic achievement and how that became one of the most pivotal moments in her career!
#youtubeshorts from @ProgressPotentialPossibilities Jerry McLaughlin - Chief Executive Officer and Board Member - Life Biosciences - Developing Novel Therapies To Extend Healthy Human Lifespan https://www.youtube.com/watch?v=CKveyn95CaY #ProgressPotentialAndPossibilities #DavidSinclair #Aging #Longevity #Healthspan #Lifespan #DrugDevelopment #Biotechnology #Autophagy #CellularReprogramming
On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Life Biosciences' CSO, Sharon Rosenzweig-Lipson, Ph.D., about the Boston-based biotech's cellular rejuvenation therapies for the treatment of age-related diseases. They cover Life Biosciences' lead program, a gene therapy called OSK that is being advanced in two optic neuropathies – a rare eye disease of aging called non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. They also cover the why behind gene therapy as a modality, as well as Life Biosciences' partnership with Forge Biologics to manufacture AAV for cellular rejuvenation technology. -- #celltherapy #genetherapy Subscribe to the podcast! Apple - https://podcasts.apple.com/us/podcast/cell-gene-the-podcast/id1574496063 Spotify - https://open.spotify.com/show/78NSjRuHndVhI5VHWWAMya Google - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5idXp6c3Byb3V0LmNvbS8xODEwNDgyLnJzcw==
Life Biosciences, a company co-founded by Dr. David Sinclair is developing novel Chaperone-Mediated Autophagy Activator Compounds. Dr. Jerry McLaughlin, CEO of Life Biosciences presents the goal and the progress of the project in this video. https://pubmed.ncbi.nlm.nih.gov/34110247/ https://pubmed.ncbi.nlm.nih.gov/29626215/ https://pubmed.ncbi.nlm.nih.gov/33442062/ https://pubmed.ncbi.nlm.nih.gov/36383673/ https://pubmed.ncbi.nlm.nih.gov/35363568/ David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming. Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and h
Life Biosciences, a company co-founded by Dr. David Sinclair is developing the next-generation of Mitochondrial Uncoupling compounds. Dr. Jerry McLaughlin, CEO of Life Biosciences presents the goal and the progress of the project in this video. https://www.sciencedirect.com/science/article/pii/S0925443923002740?via%3Dihub https://pubmed.ncbi.nlm.nih.gov/32409697/ https://www.nature.com/articles/s41467-020-16298-2 https://pubmed.ncbi.nlm.nih.gov/34627389/ https://pubmed.ncbi.nlm.nih.gov/37900126/ David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming. Dr David Sinclair has suggested that aging is a disease—and that we may s
Dr. David Sinclair talks about the mechanism of how Red Light Therapy works and the amazing benefits of it in this short. Please note that the links below are affiliate links, so we receive a small commission when you purchase a product through the links. Thank you for your support! =*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*= ~*~ Discount Coupon Code : REVERSE ~*~ 🌏ProHealth Longevity All Products15% OFF 🧬 DoNotAge All Products 10% OFF 🔬Renue By Science All Products 10% OFF ~*~ Discount Coupon Code : REVERSEAGING20 🔶 Nuchido Time+ Supplement FIRST ORDER 20% OFF =*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*= David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolis
Jerry McLaughlin is Chief Executive Officer and Board Member of Life Biosciences, Inc. ( https://www.lifebiosciences.com/ ), a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan, pursuing a platform approach to develop therapeutics that can prevent, treat, and/or reverse multiple aging-related conditions. Jerry has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA- approved drugs with multiple successful exits. Most recently, Jerry was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, he served as president and CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of senior vice president & chief commercial officer at NuPathe Inc., acquired by Teva Pharma
Join LBA members James Peyer and Nir Barzilai in an insightful discussion with Jerry McLaughlin, CEO of Life Biosciences. Learn from Jerry's extensive experience in senior leadership roles at pharmaceutical companies and his involvement in the development of statins. Discover valuable lessons for geroscience therapeutics as we venture into clinical trials, and gain insights from Jerry's wealth of knowledge.
Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.” The fountain of youth might be a fantasy, but the biology of aging, and more specifically, the science behind the manipulation of that biology, is not only real, it’s become big business. Still, the challenge for serious and legitimate biopharmaceutical companies in the anti-aging space can sometimes have less to do with biology than perception. Does the biotech investment community understand and embrace the concept? Equally, if not more importantly, will the FDA and other regulatory agencies lean into the idea that aging itself might be viewed as an indication that warrants therapeutic review? And from a commercial perspective, how does a legitimate biopharmaceutical company, focused on combatting the physical deterioration marked by the
Meet the Healthy Longevity Innovators This panel convenes some of the most promising startups working in the field of healthy longevity. Each innovator will provide a peek at the companies’ missions, business models, and visions for a healthier future. 0:00 Introduction: Dr. William Greene, Chief Investment Officer, Hevolution Foundation 03:03 Why did you start or join your current company? 03:16 Dr. Gregory Bailey, Co-founder, Executive Chairman and Former CEO, Juvenescence, Isle of Man 04:31 Dr. Ann Beliën, Founder & CEO, Rejuvenate Biomed, Belgium 05:57 Kristen Fortney, PhD, CEO & Co-founder, BioAge Labs, United States 07:22 Dr. Anuj Gaggar, Co-Founder & CEO, Arrive Bio, Singapore 08:51 Jerry McLaughlin, CEO, Life Biosciences, United States 10:43 What are the biggest hurdles you've encountered in your journey, and how are you addressing them? 11:02 Kristen Fortney, PhD, CEO & Co-founder, BioAge Labs, United States 12:24 Dr. Anuj Gaggar, Co-Founder & CEO, Arrive Bio, Singapore 14:1
Life Biosciences is developing innovative therapies to transform how we treat diseases by targeting aging biology. Emerging Company Showcase Targeting Metabesity October 13, 2022
Dr David Sinclair talks about the progress on reprogramming and restoring vision in humans is his company’s first mission on reprogramming in this clip. David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming. Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and he has called for greater international attention to the social, economic and political and benefits of a world in which billions of people can live much longer and much healthier lives. Dr David Sinclair is the co-founder of several biotechnology companies (Life Biosciences, Sirtris, Genocea, Cohba
Dr David Sinclair explain what is senolytics, especially quercetin and fisetin, other than reducing senescent cells, both has another amazing benefit behind them. https://pubmed.ncbi.nlm.nih.gov/12939617/ Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan 2003 paper https://pubmed.ncbi.nlm.nih.gov/29988130/ Senolytics improve physical function and increase lifespan in old age David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming. Dr David Sinclair has suggested that aging is a disease—and that we may soon have the tools to put it into remission—and he has called for greater international attenti
A Metabesity 2021 Emerging Company Showcase presentation on Life Biosciences by Jerry McLaughlin, MBA, Chief Executive Officer. Life Biosciences is pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Our platform approach enables us to develop pharmaceutical treatments with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs.
A Metabesity conference session answering the questions: Are companies entering healthy longevity space? What new business models of commercializing healthy longevity are emerging? How are investors reacting to developments? Moderators: Joe Cook, Jr., Executive Chairman and President of NuSirt Biopharma; former Chairman and CEO of Amylin, USA Dennis Purcell, Founder and Senior Advisor of Aisling Capital, USA Ed Saltzman, Executive Chairman, Cello Health BioConsulting, USA Speakers: Philipp Gut, MD, Department Head at Nestlé Institute of Health Sciences, Nestlé Research, Switzerland Roman Kalista, MD, Co-founder and CEO of RxDiet, USA Jerry McLaughlin, MBA, CEO and Board Member of Life Biosciences, Inc., USA Casey Means, MD, Chief Medical Officer and Co-founder of Levels Health, USA James Peyer, PhD, Founder and CEO of Cambrian BioPharma, USA Pietro Antonio Tataranni, MD, Chief Medical Officer and Senior Vice President of Life Sciences at PepsiCo, USA